Radiodermatitis Market By Product (Topical, Dressing, Oral) - Growth, Future Prospects And Competitive Analysis, 2017 - 2025

According to American Society for Radiation Oncology 2010 report approximately 75% of oncology patients opt for radiation therapy. The primary aim of radiation therapy is to irradiate the tumor cells, however the normal cells being exposed to the radiation therapy get damaged. Normal tissue cells are capable of self-repair but the repetitive damage reduces the reparation properties of normal cells. Factors that increase the risk and severity of skin reactions include high daily cumulative radiation doses, the type of beam utilized for irradiation, large treatment field, treatment to areas with skin folds and whether the radiation was given with chemotherapy.

For the purpose of this study, the various products studied includes topical, dressing and oral. Topical are further classified as (antibiotics, hydrophilic creams, corticosteroids and others). Dressing are categorized as (no string barrier films, honey impregnated gauze, hydrogel and hydrocolloid dressings, silicone coated dressings and others). Market size estimates and forecast of these segments for the period 2015 to 2025 are provided in terms of US$ Mn along with the respective CAGRs for the period 2017 to 2025, considering 2016 as the base year.

The geographic segmentation of the global radiodermatitis market is performed for the regions North America, Europe, Asia Pacific, Latin America and Middle East and Africa markets. The regions are also further sub-segmented on the basis of major countries:

  • North America
    • U.S.
    • Canada
  • Europe
    • U.K.
    • Germany
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • Rest of Asia Pacific
  • Latin America
    • Mexico
    • Brazil
    • Rest of Latin America
  • Middle East and Africa
    • GCC
    • Rest of Middle East and Africa

Market size estimates and forecast for these segments for the period 2015 to 2025 are provided in terms of US$ Mn along with the respective CAGRs for the period 2017 to 2025, considering 2016 as the base year.

This report also includes qualitative assessment factors such as market dynamics (drivers, restraints and opportunities) to have a good understanding of the current and anticipated trends in the global radiodermatitis market. Market attractiveness assessment and competitive landscape analysis by key players are also presented in the study. Furthermore, this report concludes with profiling of key market players currently enjoying prominent position in the global radiodermatitis market. The major players in radiodermatitis market are Acelity, Alliqua Biomedical, BMG Pharma S.R.L., Convatec, Inc., Derma Sciences, Inc., Intermed Pharmaceuticals, Molnlycke Health Care AB, Smith & Nephew plc, Stratpharma AG and 3M Healthcare.

Radiodermatitis Market

For the purpose of this study, the global radiodermatitis market is categorized into the following regional and country specific markets:

  • North America
    • U.S.
    • Canada
  • Europe
    • U.K.
    • Germany
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East and Africa
    • GCC
    • Rest of Middle East and Africa

Radiodermatitis Market

North America will be the fastest growing market for radiodermatitis throughout the forecast period 2017-2025. According to the American Cancer Society, in 2017, about 1,688,780 new cancer cases were diagnosed. The dominance of North America is mainly attributed to the presence of key drivers such as rising prevalence of cancer, first treatment preference to treat cancer is given to radiation therapy, and developed research and healthcare institutions. The market growth in Europe is mainly attributed to the increasing prevalence of radiodermatitis and rising fashion trend has resulted in the demand for radiation therapy to enhance the aesthetic appeal of personal beauty and affordable reimbursement scenario.

Asia Pacific dominated the radiodermatitis market for the base year 2016 and the factors that are anticipated to propel the market growth are the increasing number of chronic health complications resulting into demand for radiation therapy, competitive market due to presence of existing major and evolving players engaged in the manufacturing and sale of radiodermatitis products in these regions, increasing disposable incomes and supportive regulatory environment for radiodermatitis products. Moreover, factors such as developing healthcare infrastructure, extensive collaborations undertaken by pharmaceutical giants to expand their product portfolio in the untapped markets of developing areas with unmet medical needs are going to fuel the rapid growth of radiodermatitis market in Latin America, and Middle East and Africa region in the near future.   

Choose License Type
Published Date:  Sep 2017
Category:  Pharmaceuticals
Report ID:   58693
Report Format:   PDF
Pages:   120
Rating:    4.3 (60)
Connect With Us
+1-408-641-3282
24/7 Research Support